- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT02006160
Effects of Dalfampridine on Cognition in Multiple Sclerosis
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
3a. Patient Sample and Recruitment
Subjects will be consecutively selected from the Western New York (NY) region where the Baird MS Center and the Jacobs Neurological Institute are located. Patients will be interviewed and their records reviewed to assess for inclusion/exclusion. Patients will then be approached in the clinic or contacted by telephone and invited to participate in this clinical trial. The attached flier will also be used to directly advertise the study to patients. Patients who initiate contact with the researcher will be interviewed to assess eligibility.
Inclusion Criteria. Patients will be eligible for the study if they fulfill all the inclusion criteria specified below
- Males/Females who are ≥ 18 years old and < 65 years old and are capable of understanding and complying with the protocol, including speaking and writing fluent English and having at least a 9th grade education.
- Have a diagnosis of MS, as per revised McDonald's Criteria.
- Have not received steroids in last thirty (30) days or a relapse in the last ninety (90) days, and whose MS is considered stable.
- Impression of cognitive impairment as indicated by one of the following: (a) positive NP testing following diagnosis of MS as determined by board certified neuropsychologist or with z scores <-1.5 below expectation in at least one cognitive domain, or (b) informant Multiple Sclerosis Neuropsychological Questionnaire (MSNQ) >28.
- An Expanded Disability Status Scale (EDSS) of ≤ 6.5.
- Have given written informed consent prior to any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to his/her future medical care.
- Are capable of performing the requirements of a NP test battery including at least 20/70 near visual acuity by near vision chart, with correction allowed.
- If female, must neither be pregnant nor breast-feeding and must either (a) be > 12 months post-menopausal or surgically sterilized, or (b) agree to use an acceptable method of birth control for the duration of the study. Abstinence will not be considered an acceptable method of birth control.
Exclusion Criteria. Patients will be excluded from the study if they meet any one or more of the exclusion criteria specified below:
- Have cognitive deficits caused by concomitant medication usage or other significant neurological/psychological disease e.g. Alzheimer's disease, Parkinson's disease, stroke, transient ischemic attack, Vascular Dementia, Huntington's disease, traumatic brain injury or chronic central nervous system (CNS) infection
- Have evidence of other medical cause(s) of cognitive impairment
- Evidence of major mental illness predating the onset of MS
- Have evidence of major depression as determined by a positive Beck Depression Index-Fast Screen (BDIFS) and clinician interview
- Have report of uncontrolled or labile hypertension, tachycardia, cardiovascular or cerebrovascular disease
- History of seizure disorder.
- Optic neuritis within 6 months of enrollment.
- Trigeminal neuralgia.
- Prior exposure to aminopyridines.
Additional Exclusion Criteria for optional speech module. Patients will not be eligible for enrollment in the optional speech module is they meet one or more of the exclusion criteria below:
- Have any language/dialect other than Standard American English as their first language.
- Make use of a mechanical hearing aid.
3b. Outcome Measures
Cognition Endpoints. Psychometric testing will incorporate gold standard tests from validated test batteries by Benedict et al and Rao et al [7-9, 47-49]. The test order is described below:
Table 2. Cognitive Battery Test Domain Time in min California Verbal Learning Test 2 (CVLT2) Learning Trials Auditory/Verbal Memory 15 Brief Visuospatial Memory Test Revised (BVMTR) Learning Trials Visual/Spatial Memory 05 Paced Auditory Serial Addition Test (PASAT) 3 sec Auditory Processing Speed 05 Symbol Digit Modalities Test (SDMT) Visual Processing speed 05 Delis Kaplan Executive Function System (DKEFS) Sorting Test Executive Function 12 California Verbal Learning Test 2 (CVLT2) Delayed Recall Auditory/Verbal Memory 05 Brief Visuospatial Memory Test Revised (BVMTR) Delayed Recall Visual/Spatial Memory 03 Total Time 50 min
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 2
- Faza 3
Kontakty i lokalizacje
Lokalizacje studiów
-
-
New York
-
Buffalo, New York, Stany Zjednoczone, 14203
- Buffalo General Hospital
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
Patients will be eligible for the study if they fulfill all the inclusion criteria specified below:
- Males/Females who are ≥ 18 years old and < 65 years old and are capable of understanding and complying with the protocol, including speaking and writing fluent English and having at least a 9th grade education.
- Have a diagnosis of MS, as per revised McDonald's Criteria.
- Have not received steroids in last thirty (30) days or a relapse in the last ninety (90) days, and whose MS is considered stable.
- Impression of cognitive impairment as indicated by one of the following: (a) positive NP testing following diagnosis of MS as determined by board certified neuropsychologist or with z scores <-1.5 below expectation in at least one cognitive domain, or (b) informant MSNQ >28.
- An Expanded Disability Status Scale (EDSS) of ≤ 6.5.
- Have given written informed consent prior to any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to his/her future medical care.
- Are capable of performing the requirements of a NP test battery including at least 20/70 near visual acuity by near vision chart, with correction allowed.
- If female, must neither be pregnant nor breast-feeding and must either (a) be > 12 months post-menopausal or surgically sterilized, or (b) agree to use an acceptable method of birth control for the duration of the study. Abstinence will not be considered an acceptable method of birth control.
Exclusion Criteria:
- Have cognitive deficits caused by concomitant medication usage or other significant neurological/psychological disease e.g. Alzheimer's disease, Parkinson's disease, stroke, transient ischemic attack, Vascular Dementia, Huntington's disease, traumatic brain injury or chronic CNS infection
- Have evidence of other medical cause(s) of cognitive impairment
- Evidence of major mental illness predating the onset of MS
- Have evidence of major depression as determined by a positive BDIFS and clinician interview
- Have report of uncontrolled or labile hypertension, tachycardia, cardiovascular or cerebrovascular disease
- History of seizure disorder.
- Optic neuritis within 6 months of enrollment.
- Trigeminal neuralgia.
- Prior exposure to aminopyridines within the last six months.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Poczwórny
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Komparator placebo: kontrola
placebo
|
10 mg bid
|
Aktywny komparator: treatment
dalfampridine
|
10 mg bid
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Symbol Digit Modalities Test
Ramy czasowe: Week 0, Week 12
|
The Symbol Digit Modalities Test is a measure of cognitive processing speed.
The outcome is the total number of correct digit substitutions in 90 seconds, with a possible total range of 0-120.
Higher values reflect a better score/outcome than lower scores.
|
Week 0, Week 12
|
Współpracownicy i badacze
Śledczy
- Główny śledczy: Ralph Benedict, PhD, University at Buffalo
- Główny śledczy: Bianca Weinstock-Guttman, MD, University at Buffalo
Publikacje i pomocne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
- Procesy patologiczne
- Choroby Układu Nerwowego
- Choroby układu odpornościowego
- Demielinizacyjne choroby autoimmunologiczne, OUN
- Choroby Autoimmunologiczne Układu Nerwowego
- Choroby demielinizacyjne
- Choroby Autoimmunologiczne
- Stwardnienie rozsiane
- Skleroza
- Molekularne mechanizmy działania farmakologicznego
- Modulatory transportu membranowego
- Blokery kanału potasowego
- 4-aminopirydyna
Inne numery identyfikacyjne badania
- NEU3270511E
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Stwardnienie rozsiane
-
Teva Branded Pharmaceutical Products R&D, Inc.ZakończonyRelapse Remiting Sclerosis Multiplex
-
Novartis PharmaceuticalsRekrutacyjnyRelapse Remiting Sclerosis MultiplexStany Zjednoczone, Portoryko
-
Teva Branded Pharmaceutical Products R&D, Inc.ZakończonyRelapse Remiting Sclerosis Multiplex
-
Thomas Jefferson UniversityRekrutacyjnyRelapse Remiting Sclerosis MultiplexStany Zjednoczone
-
Novartis PharmaceuticalsZakończonyRelapse Remiting Sclerosis MultiplexStany Zjednoczone, Ukraina, Czechy
-
Thomas Jefferson UniversityRekrutacyjnyRelapse Remiting Sclerosis MultiplexStany Zjednoczone